DNLIHealthcareMid-Cap
Denali Therapeutics Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Denali Therapeutics Inc. (DNLI), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud Research Team · SEC Form 4 & insider trading data analysts
Last updated:
Quick Answer
Are DNLI insiders buying or selling?
Denali Therapeutics Inc. insiders reported 0 open-market buys ($0) and 233 sells ($470.1M) across 233 Form 4 filings — a net selling position of $470.1M.
Source: SEC EDGAR Form 4
Key Statistics (as of Jan 8, 2026)
Total Form 4 filings
233
SEC EDGAR
Insider filers
9
Insider buys (0)
$0
Insider sells (233)
$470.1M
Insider sentiment
Net sellingNet insider flow of $470.1M in net selling.
Recent DNLI insider transactions
| Date | Insider | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jan 8, 2026 | Ryan J. Watts | President and CEO | Sale | 35.2K | $16.50 | $580.8K |
| Jan 8, 2026 | Alexander O. Schuth | COFO and Secretary | Sale | 17.2K | $16.50 | $284.1K |
| Aug 15, 2025 | Alexander O. Schuth | COFO and Secretary | Sale | 2.9K | $13.58 | $39.9K |
| Aug 15, 2025 | Carole Ho | Chief Medical Officer | Sale | 3.7K | $13.81 | $51.7K |
| Jul 11, 2025 | Ryan J. Watts | President and CEO | Sale | 495.3K | $15.00 | $7.4M |
| Jan 9, 2025 | Carole Ho | Chief Medical Officer | Sale | 15.2K | $20.33 | $308.3K |
| Jan 9, 2025 | Alexander O. Schuth | COFO and Secretary | Sale | 15.2K | $20.33 | $308.3K |
| Jan 9, 2025 | Ryan J. Watts | President and CEO | Sale | 36.9K | $20.34 | $751.0K |
| Jan 9, 2025 | Steve E. Krognes | Director | Sale | 3.3K | $20.81 | $69.5K |
| Jan 3, 2025 | Steve E. Krognes | Director | Sale | 30.0K | $20.25 | $607.5K |
| Jan 3, 2025 | Vicki L Sato | Director | Sale | 3.1K | $20.91 | $64.4K |
| Nov 13, 2024 | David P Schenkein | Director | Sale | 59.4K | $32.51 | $1.9M |
| Nov 12, 2024 | Alexander O. Schuth | COFO and Secretary | Sale | 15.6K | $29.91 | $465.3K |
| Nov 12, 2024 | Vicki L Sato | Director | Sale | 1.0K | $30.00 | $30.6K |
| Nov 5, 2024 | Vicki L Sato | Director | Sale | 3.1K | $27.07 | $83.4K |
| Oct 22, 2024 | Ryan J. Watts | President and CEO | Sale | 40.0K | $27.69 | $1.1M |
| Oct 2, 2024 | Steve E. Krognes | Director | Sale | 30.0K | $29.03 | $870.9K |
| Sep 16, 2024 | Vicki L Sato | Director | Sale | 1.0K | $30.00 | $30.6K |
| Sep 4, 2024 | Vicki L Sato | Director | Sale | 3.1K | $25.00 | $77.0K |
| Aug 22, 2024 | Ryan J. Watts | President and CEO | Sale | 2.3K | $23.79 | $53.8K |
| Aug 22, 2024 | Steve E. Krognes | Director | Sale | 1.7K | $23.79 | $41.1K |
| Aug 22, 2024 | Alexander O. Schuth | COFO and Secretary | Sale | 8.4K | $23.99 | $200.4K |
| Aug 22, 2024 | Carole Ho | Chief Medical Officer | Sale | 22.5K | $24.49 | $549.9K |
| Aug 15, 2024 | Alexander O. Schuth | COFO and Secretary | Sale | 2.3K | $22.89 | $52.0K |
| Aug 15, 2024 | Carole Ho | Chief Medical Officer | Sale | 2.3K | $22.89 | $53.5K |
Showing the 25 most recent of 233 Form 4 filings for Denali Therapeutics Inc..
Most active DNLI insiders
- Alexander O. Schuth53 filings
- Carole Ho51 filings
- Ryan J. Watts51 filings
- Vicki L Sato28 filings
- Steve E. Krognes23 filings
Ask anything about DNLI insider activity
Use Trabud's AI agent to query Denali Therapeutics Inc.'s Form 4 history in plain English — "Show me DNLI CEO purchases this year" or compare it against any other ticker.
Open the AI agentDNLI insider trading FAQ
Are Denali Therapeutics Inc. insiders buying or selling?
Across 233 SEC Form 4 filings, Denali Therapeutics Inc. (DNLI) insiders reported 0 open-market purchases totaling $0 and 233 sales totaling $470.1M. That is a net selling position of $470.1M.
How many insiders trade DNLI stock?
9 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Denali Therapeutics Inc.. The most recent filing was accepted on Jan 8, 2026.
Where does Trabud get DNLI insider trading data?
All DNLI insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.
Looking for another company? Browse all tracked companies.